Targeting JAK3 and HOXA9 to Combat T-Cell ALL?
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable.
Source: CancerNetwork - Category: Cancer & Oncology Authors: John Schieszer Tags: Acute Lymphoblastic Leukemia Hematologic Malignancies News Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Hematology | Leukemia